1. Volume 134, Issue 2, Pages 622-625 (February 2008)
Endocannabinoids, CB1 Receptors, and Liver Disease: Hitting More Than One Bird With the Same Stone 
George Kunos, Bin Gao 
Gastroenterology 
Volume 134, Issue 2, Pages (February 2008)
DOI: /j.gastro
Copyright © 2008 AGA Institute Terms and Conditions

2. Figure 1
Schematic representation of the hepatic fibrogenic and steatogenic actions of endocannabinoids. Fibrogenic stimuli, such as CCl4 or ethanol, selectively induce 2-AG production in stellate cells.10,30 2-AG can then activate CB1 receptors on stellate cells to induce fibrogenesis,7 or on adjacent hepatocytes to induce de novo lipogenesis.10 Lipogenic stimuli, such as a high-fat diet, induces anandamide (AEA) production and CB1 expression in hepatocytes, activation of which increases de novo lipogenesis and inhibits fatty acid β-oxidation.9Abbreviations: FAAH, fatty acid amidohydrolase; AMPK, AMP-activated protein kinase; SREBP1c, sterol response element binding protein-1c; ACC1, acetyl CoA carboxylase-1; FAS, fatty acid synthase; SCD1, stearoyl CoA desaturase-1; CPT1, carnitine palmitoyl transferase-1.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2008 AGA Institute Terms and Conditions